Medication info
Duvimet ER Tablets 0.25/50/500 mg

Duvimet ER Tablets 0.25/50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletLobeglitazone Sulfate›0.25mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Light blue, bilaterally convex, oval-shaped extended-release film-coated tablet
Packaging
Bottle package - 30 tablets/bottle, bottle package - 6 tablets/bottle
Approval status
Active

MFDS item code 202301432 · Approved 2023.05.02 · Insurance code 643309350

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is lobeglitazone sulfate 0.5 mg and sitagliptin 100 mg; the dose of extended-release metformin hydrochloride should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. This medicine is generally administered once daily with the evening meal, and the dose is adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 0.5/100/1000 mg extended-release tablet once daily. Patients taking this medicine 0.25/50/500 mg, 0.25/50/750 mg, or 0.25/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with metformin and sitagliptin, the starting dose of this medicine should be lobeglitazone sulfate 0.5 mg, sitagliptin 100mg, and the dose of metformin hydrochloride currently being taken, or an appropriate dose therapeutically equivalent to it. For patients switching from combination therapy with lobeglitazone, sitagliptin, and metformin to this medicine, the dose of this medicine should be the existing dose of each component. No dose adjustment is necessary in patients with mild renal impairment [estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this medicine may be used by adjusting the metformin hydrochloride dose if it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or estimated glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication assists adult patients with type 2 diabetes in managing their blood sugar by combining Rosiglitazone, Sitagliptin, and Metformin. The effectiveness can be enhanced when accompanying dietary and exercise therapies. It effectively manages blood sugar levels and contributes to the prevention of diabetes-related complications. It is used to improve blood sugar control in patients.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is lobeglitazone sulfate 0.5 mg and sitagliptin 100 mg; the dose of extended-release metformin hydrochloride should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. This medicine is generally administered once daily with the evening meal, and the dose is adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 0.5/100/1000 mg extended-release tablet once daily. Patients taking this medicine 0.25/50/500 mg, 0.25/50/750 mg, or 0.25/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with metformin and sitagliptin, the starting dose of this medicine should be lobeglitazone sulfate 0.5 mg, sitagliptin 100mg, and the dose of metformin hydrochloride currently being taken, or an appropriate dose therapeutically equivalent to it. For patients switching from combination therapy with lobeglitazone, sitagliptin, and metformin to this medicine, the dose of this medicine should be the existing dose of each component. No dose adjustment is necessary in patients with mild renal impairment [estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this medicine may be used by adjusting the metformin hydrochloride dose if it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or estimated glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine should be discontinued immediately.

Precautions

This medication should not be used in patients with compromised cardiac function, as it may worsen symptoms of heart failure; careful monitoring by a physician is needed. If signs of heart failure appear, consult a doctor immediately and get evaluated through necessary tests. It is also recommended not to initiate this medication in severely symptomatic heart failure patients. This medication may cause fluid retention, leading to edema or heart failure symptoms, thus patients should periodically monitor these symptoms. Allergic reactions may occur, and if symptoms such as rash, hives, or difficulty breathing appear, discontinue use immediately and inform healthcare personnel. There is a risk of serious pancreatic diseases, such as pancreatitis; thus, if symptoms like abdominal pain, nausea, or vomiting occur, seek medical attention promptly. This medication can rarely cause a serious metabolic disorder called lactic acidosis; if symptoms like sudden fatigue, muscle pain, difficulty breathing, or abdominal pain arise, consult your healthcare provider immediately. Patients with renal function impairment should not use this medication and should have regular kidney function tests. Caution is also required in patients with liver dysfunction, and the medication may be discontinued if liver test results are abnormal. During therapy, any weight gain or edema should be reported to a physician, and it is crucial to combine appropriate exercise with a dietary regimen. This medication carries a risk of hypoglycemia, requiring caution when skipping meals or engaging in vigorous exercise, and immediate action is necessary if hypoglycemic symptoms occur. Pregnant women or those planning to become pregnant should consult a physician before use, while premenopausal women should use adequate contraceptive methods during treatment due to the risk of pregnancy. If one's physical condition is poor due to surgery or severe infections, temporary discontinuation of this medication is recommended, and it may be restarted upon recovery as advised by a doctor. This medication may interact with other drugs; thus, if you are taking any other medications, it is essential to inform your physician or pharmacist. Regular testing of blood sugar, liver function, and kidney function should be done during treatment, and any adverse symptoms should be reported to healthcare personnel immediately.

Side effects

  • Congestive heart failure
  • excessive and rapid weight changes
  • dyspnea
  • edema
  • severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • severe lactic acidosis
Show 190 more
  • hypoglycemia
  • nasopharyngitis
  • headache
  • dyspepsia
  • epigastric pain
  • cataract
  • tinnitus
  • edema
  • ligament sprain
  • hyperlipidemia
  • pruritus
  • osteoarthritis
  • myalgia
  • fracture
  • arthralgia
  • hematuria
  • elevated ALT
  • elevated AST
  • fatty liver
  • dizziness
  • sensory disturbances
  • diabetic retinopathy
  • palpitations
  • hypertension
  • anemia
  • shingles
  • breast discomfort
  • constipation
  • chronic gastritis
  • gastroesophageal reflux disease
  • hyperglycemia
  • cold
  • upper respiratory infection
  • cough
  • weight gain
  • neck/shoulder pain
  • ligament disorder
  • tinnitus
  • insomnia
  • atherosclerosis
  • irritable bowel syndrome
  • colon polyp
  • peritonitis
  • gastritis
  • bowel obstruction
  • appendicitis
  • exacerbation of pancreatitis
  • kidney cancer
  • cholangiocarcinoma
  • gastric cancer
  • breast cancer
  • lung cancer
  • rib fracture
  • osteoporotic fracture
  • pelvic fracture
  • pneumonia
  • acute respiratory distress syndrome
  • exacerbation of asthma
  • epiglottitis
  • surgical intervention
  • intervertebral disc disease
  • cholangitis
  • gallstones
  • hyperglycemia
  • increased blood sugar
  • brainstem infarction
  • syncope
  • subdural hemorrhage
  • angioedema
  • vomiting
  • gastrointestinal discomfort
  • gastroenteritis
  • oral ulcer formation
  • blood in stool
  • epigastric discomfort
  • loose stools
  • erosive gastritis
  • esophagitis
  • exacerbation of dysphagia
  • gastric ulcer
  • oral ulcer formation
  • gingivitis
  • periodontitis
  • hemorrhoids
  • exacerbation of hemorrhoids
  • toothache
  • exacerbation of hypercholesterolemia
  • increased fasting blood sugar
  • increased glycated hemoglobin
  • vitamin D deficiency
  • dyslipidemia
  • increased low-density lipoprotein
  • weight loss
  • gout
  • increased serum cholesterol
  • pelvic pain
  • periorbital edema
  • exacerbation of edema
  • flank pain
  • low back pain
  • generalized edema
  • generalized weakness
  • leg edema
  • inadequate effect
  • acute respiratory distress syndrome
  • bronchitis
  • chronic obstructive pulmonary disease
  • chronic laryngitis
  • throat infection
  • atelectasis
  • sinusitis
  • shortness of breath
  • exacerbation of asthma
  • epistaxis
  • dyspnea
  • pulmonary edema
  • polyneuropathy
  • cognitive impairment
  • skin tingling
  • eye twitching
  • leg cramps
  • simple partial seizure
  • peripheral sensory neuropathy
  • speech impairment
  • exacerbation of dizziness
  • spinal stenosis
  • cystitis
  • nocturia
  • increased serum creatinine
  • dysuria
  • frequent urination
  • nephrotic syndrome
  • ureteral stones
  • urinary tract infection
  • rib fracture
  • shoulder girdle syndrome
  • costochondritis
  • leg fracture
  • temporomandibular joint dysfunction
  • elbow deformity
  • tinea capitis
  • keratosis
  • psoriasis
  • exacerbation of psoriasis
  • acute urticaria
  • onychomycosis
  • eyelash syndrome
  • onychomycosis
  • hair loss
  • skin nodules
  • skin peeling
  • dermographism
  • erythematous rash
  • corneal deposits
  • conjunctivitis
  • ocular hypertension
  • lacrimal duct obstruction
  • chorioretinal disorder
  • exacerbation of cataract
  • vision reduction
  • ocular infection
  • epidermoid cyst
  • polycythemia
  • erectile dysfunction
  • anxious reaction
  • depression
  • depressed mood
  • mental disorder
  • confusion
  • skin laceration
  • knee arthroplasty
  • herniated disc
  • dry eye syndrome
  • toxocariasis
  • genital myiasis
  • vaginal candidiasis
  • increased TSH
  • hyperthyroidism
  • sialadenitis
  • vaginitis
  • cervical dysplasia
  • menopausal symptoms
  • intermittent claudication
  • aortic atherosclerosis
  • coronary artery occlusion
  • male perineal pain
  • atrial fibrillation
  • ventricular extrasystole
  • discoid lupus erythematosus
  • bruising

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Light blue, bilaterally convex, oval-shaped extended-release film-coated tablet

Package unit

Bottle package - 30 tablets/bottle, bottle package - 6 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.